Quizartinib can prolong OS in rel/ref, FLT3-ITD AML

Print Friendly, PDF & Email


The 23rd Congress of the European Hematology Association
Phase 3 results suggest the FLT3 inhibitor quizartinib can prolong overall survival (OS) in patients with relapsed/refractory, FLT3-ITD acute myeloid leukemia (AML). In the QuANTUM-R study, patients who received single-agent quizartinib had a significantly longer median OS than patients who received salvage chemotherapy. There was a... [Read Article]
Print Friendly, PDF & Email

Ivosidenib active in R/R IDH1-mutated AML patients

Print Friendly, PDF & Email


Poster session at ASCO 2018
Photo by © ASCO/Scott Morgan 2018
The investigational drug ivosidenib, an inhibitor of the mutant IDH1 enzyme, achieved complete remission (CR) rates of 32% and an overall response rate of 42% in relapsed/refractory (R/R) patients with acute myeloid leukemia (AML) and IDH1 mutation, according to investigators. In addition, overall survival... [Read Article]
Print Friendly, PDF & Email

Protein may be therapeutic target for AML

Print Friendly, PDF & Email


AML cells
Image by Lance Liotta
A signaling protein may be a “potent” therapeutic target for acute myeloid leukemia (AML), according to a paper published in the Journal of Experimental Medicine. The protein, interleukin-1 receptor accessory protein (IL1RAP), is often highly expressed on the surface of leukemic stem cells (LSCs) but largely absent from... [Read Article]
Print Friendly, PDF & Email

NCCN releases guidelines for AML patients

Print Friendly, PDF & Email


Cancer patient
receiving treatment
Photo by Rhoda Baer
The National Comprehensive Cancer Network (NCCN) has released guidelines for patients with acute myeloid leukemia (AML). The guidelines are intended to help patients make better informed decision about their care. These guidelines explain what AML is, describe testing procedures and treatment options, and provide tips... [Read Article]
Print Friendly, PDF & Email

CAR T-cell therapy bridges to HSCT in AML patient

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
A case report suggests an investigational chimeric antigen receptor (CAR) T-cell therapy can provide a bridge to transplant in relapsed/refractory acute myeloid leukemia (AML). The therapy, known as CYAD-01, prompted a morphologic leukemia-free state in an AML patient. This patient went on to receive an allogeneic hematopoietic... [Read Article]
Print Friendly, PDF & Email

Y chromosome gene protects against AML

Print Friendly, PDF & Email


Micrograph showing AML
Image from Paulo
Henrique Orlandi Mourao
Researchers have discovered the first leukemia-protective gene that is specific to the Y chromosome, according to an article published in Nature Genetics. The researchers were investigating how loss of the X-chromosome gene UTX hastens the development of acute myeloid leukemia (AML). However, they found... [Read Article]
Print Friendly, PDF & Email

GO approved to treat AML in Europe

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
The European Commission has authorized use of gemtuzumab ozogamicin (GO, Mylotarg™) as a treatment for patients with acute myeloid leukemia (AML). GO is now approved for use in combination with daunorubicin and cytarabine to treat patients age 15 and older who have previously untreated, de novo, CD33-positive... [Read Article]
Print Friendly, PDF & Email